Primary Pleural Squamous Cell Carcinoma, Highly Positive PD-L1, Shows Marked Response to Camrelizumab: A Case Report. (July 2021)

• Record Type: Journal Article
• Authors: Wang, Yao; Gao, Ying; Chen, Hai-Ruo; Liu, Hong; Fu, Xi; Yan, Ran; You, Feng-Ming; Li, Zhuo-Hong
• Is Part Of: Clinical medicine insights. Oncology. Volume 15(2021)
• Publication Date: 2021-07
• Subjects: Primary pleural squamous -- camrelizumab -- therapeutic -- case report; Oncology -- Periodicals; 616.994005
• DOI: 10.1177/11795549211028571
• Languages: English
• ISSNs: 1179-5549

Abstract

Here, we reported the rare case of primary pleural squamous cell carcinoma (PPSCC) in a 71-year-old male patient. After chemo and targeted therapies, the patient showed continuous tumor progression and clinical deterioration. Fortunately, the patient had a high expression level of PD-L1 (80%) in the tumor tissues. Ultimately, the patient survived for additional 6 months with camrelizumab treatment. In summary, camrelizumab may be a good candidate for the treatment of PPSCC, especially in tumors with high PD-L1 expression.